Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15931626 | 0.90 | ABCG2 (0.44) | ABCG2PDE10AALDH1A1KDM4EMEN1 | |
| SCHEMBL15931625 | 0.90 | ABCG2 (0.44) | ABCG2PDE10AALDH1A1KDM4EBRD4 | |
| SCHEMBL6583774 | 0.89 | ABCG2 (0.49) | ABCG2PDE10AALDH1A1KDM4EPDE5A | |
| SCHEMBL14246819 | 0.88 | ABCG2 (0.43) | ABCG2PDE10AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14317881 | 0.88 | MAPT (0.47) | ABCG2PDE10AALDH1A1KDM4ETP53 | |
| SCHEMBL14317870 | 0.88 | KDM4E (0.44) | PDE10AALDH1A1KDM4ETP53MEN1 | |
| SCHEMBL14246722 | 0.88 | PDE10A (0.43) | ABCG2PDE10AALDH1A1TP53MEN1 | |
| SCHEMBL12501932 | 0.87 | ALDH1A1 (0.49) | ABCG2PDE10AALDH1A1KDM4ETP53 | |
| SCHEMBL6583824 | 0.84 | ABCG2 (0.46) | ABCG2PDE10AALDH1A1KDM4EPDE5A | |
| SCHEMBL14317180 | 0.84 | ABCG2 (0.41) | ABCG2PDE10AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| EP-1001774-B1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORP (FI) | 2004-09-15 | — | — | EP | disclosed |
| US-6774103-B1 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) | ORION CORPORATION (FI) | 2004-08-10 | — | — | US | disclosed |
| US-6538022-B1 | Three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. rational drug design enabling the | ORION CORPORATION (FI) | 2003-03-25 | — | — | US | disclosed |
| EP-1039884-B1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORP (FI) | 2002-09-18 | — | — | EP | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | ABCG2 2808/4885PDE10A 479/4885ALDH1A1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.